This could be reduced to ~2 biopsies needed to identify one patient with clinically significant fibrosis by targeting patients with elevated ALT or presence of NAFLD (with sensitivity only minimally reduced to 73%). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.